bms 986141
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02341638)
Timeline
Indications
Mechanism of action
- Proteinase activated receptor 4ANTAGONIST
F2RL3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(OCc2csc(-c3ccc(C(=O)N(C)C)cc3)n2)c2cc(-c3cn4nc(OC)sc4n3)oc2c1- Mol. weight
- 561.65 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3716552 ↗
Also known as
- bms 986141
- bms-986141
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05093790 | Phase 2 | Oct 18, 2021 | Bristol-Myers Squibb |
| NCT02985632 | Phase 1 | Jan 11, 2017 | Bristol-Myers Squibb |
| NCT03035734 | Phase 1 | Jan 1, 2017 | Bristol-Myers Squibb |
| NCT02957448 | Phase 1 | Nov 1, 2016 | Bristol-Myers Squibb |
| NCT02922452 | Phase 1 | Sep 1, 2016 | Bristol-Myers Squibb |
| NCT02671461 | Phase 2 | Apr 25, 2016 | Bristol-Myers Squibb |
| NCT02341638 | Phase 1 | Sep 1, 2014 | Bristol-Myers Squibb |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 7 | 7 | 2 | 2014 |
1 organizations
Page 1 / 1